• CervoMed presented AAIC 2026 analyses on neflamapimod in dementia with Lewy bodies, reframing Phase 2b results around Alzheimer’s co-pathology and drug exposure.
• In the 159-patient RewinD-LB trial, exploratory data favored neflamapimod on CDR-SB in patients with plasma pTau181 <21 pg/mL.
• Higher exposure in the extension (DP Batch B) showed 0.17 CDR-SB worsening versus 0.95 on placebo in the same patients (p=0.005).
• MRI readouts showed slower right basal forebrain atrophy over 16 weeks, with volume stability through 48 weeks on continued treatment.
• PK-PD work tied clinical and biomarker effects to ~4 ng/mL trough; 50 mg TID was selected for Phase 3, targeting ~90% above threshold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-023538), on July 14, 2026, and is solely responsible for the information contained therein.